772 related articles for article (PubMed ID: 33946843)
1. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions.
Hrncir T; Hrncirova L; Kverka M; Hromadka R; Machova V; Trckova E; Kostovcikova K; Kralickova P; Krejsek J; Tlaskalova-Hogenova H
Microorganisms; 2021 Apr; 9(5):. PubMed ID: 33946843
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.
Jayachandran M; Qu S
Rev Endocr Metab Disord; 2023 Dec; 24(6):1189-1204. PubMed ID: 37840104
[TBL] [Abstract][Full Text] [Related]
4. Obesity, fatty liver disease and intestinal microbiota.
Arslan N
World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
[TBL] [Abstract][Full Text] [Related]
5. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.
Bakhshimoghaddam F; Alizadeh M
Clin Nutr ESPEN; 2021 Aug; 44():61-68. PubMed ID: 34330514
[TBL] [Abstract][Full Text] [Related]
6. Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations.
Long C; Zhou X; Xia F; Zhou B
Biology (Basel); 2024 Apr; 13(4):. PubMed ID: 38666855
[TBL] [Abstract][Full Text] [Related]
7. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
8. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
Chen YH; Wu WK; Wu MS
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
[TBL] [Abstract][Full Text] [Related]
9. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of
Wang T; Ishikawa T; Sasaki M; Chiba T
Front Med (Lausanne); 2022; 9():822190. PubMed ID: 35308549
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
Han R; Ma J; Li H
Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
[TBL] [Abstract][Full Text] [Related]
11. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications.
Chen J; Vitetta L
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32717871
[TBL] [Abstract][Full Text] [Related]
12. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents.
Tokuhara D
Front Nutr; 2021; 8():700058. PubMed ID: 34250000
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease.
Zhou J; Tripathi M; Sinha RA; Singh BK; Yen PM
Hepatoma Res; 2021; 7():11. PubMed ID: 33490737
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy.
Fianchi F; Liguori A; Gasbarrini A; Grieco A; Miele L
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204274
[TBL] [Abstract][Full Text] [Related]
15. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
Meroni M; Longo M; Dongiovanni P
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
[TBL] [Abstract][Full Text] [Related]
16. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
Kirpich IA; Marsano LS; McClain CJ
Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
[TBL] [Abstract][Full Text] [Related]
17. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota, fatty liver disease, and hepatocellular carcinoma.
Chu H; Williams B; Schnabl B
Liver Res; 2018 Mar; 2(1):43-51. PubMed ID: 30416839
[TBL] [Abstract][Full Text] [Related]
20. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.
Song Q; Zhang X
Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
